Has Alan Moss received payments from drug or device companies?

Yes. Drug and device makers reported $57,821 in general payments to Alan Moss across 45 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Alan Moss did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Alan Moss come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Alan Moss

Gastroenterology · Boston, MANPI 1639378789

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $43,647 of the $57,821 with a category attached, or 75.5%. 9 manufacturers reported payments, led by Johnson & Johnson at 52.4% of the total. Reporting peaked in 2019 at $22,378 and has fallen 99.4% since, to $125 in 2025. Among gastroenterology clinicians in MA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$57,821in general payments, 2019–2025

Across 45 payments — averaging $1284.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Johnson & Johnson$30K
Pfizer$19K
Gilead$3K
Techlab, Inc.$3K
Fresenius Kabi USA, LLC$2K
Genentech USA, Inc.$125
plus $126 from 3 others

$145,603in research payments, 2019–2025

Across 13 payments — averaging $11,200 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Boehringer Ingelheim$74K
Bristol Myers Squibb$54K
Janssen Research & Development, LLC$16K
Pfizer$940
Boehringer Ingelheim RCV GmbH & Co KG$857

What the payments were for

Consulting fees$43,64775%
Speaking & faculty fees$11,40320%
Travel & lodging$1,5723%
Food & beverage$1,1992%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Johnson & Johnson	27	$30,319
Pfizer	7	$19,094
Gilead	4	$3,304
Techlab, Inc.	1	$2,973
Fresenius Kabi USA, LLC	1	$1,880
Genentech USA, Inc.	1	$125
Lilly USA, LLC	1	$84
Takeda Pharmaceuticals U.S.A., Inc.	2	$23
Olympus America Inc.	1	$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

STELARA$27,436
XELJANZ$16,094
Tremfya$2,550

How this compares

$57,821 in reported general payments places this provider in the 90th percentile of 579 gastroenterology providers in Massachusetts.

See all gastroenterology providers in Massachusetts →

Other gastroenterology in Boston

Hiroyuki AiharaBoston$728K
Jessica AllegrettiBoston$696K
John LeungBoston$682K
Ramnik XavierBoston$567K
Adam CheifetzBoston$512K
Carlo TraversoBoston$447K
Tyler BerzinBoston$215K
Marvin RyouBoston$162K
Nneka UfereBoston$153K
Christopher ThompsonBoston$127K

See the full list for Massachusetts →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →